Single and Combination Herpes Simplex Virus Type 2 Glycoprotein Vaccines Adjuvanted with CpG Oligodeoxynucleotides or Monophosphoryl Lipid A Exhibit Differential Immunity That Is Not Correlated to Protection in Animal Models

Despite several attempts to develop an effective prophylactic vaccine for HSV-2, all have failed to show efficacy in the clinic. The most recent of these failures was the GlaxoSmithKline (GSK) subunit vaccine based on the glycoprotein gD with the adjuvant monophosphoryl lipid A (MPL). In a phase 3 c...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Khodai, Tansi, Chappell, Debbie, Christy, Clare, Cockle, Paul, Eyles, Jim, Hammond, Daisy, Gore, Katrina, McCluskie, Michael J., Evans, Dana M., Lang, Susanne, Loudon, Peter T., Townend, Tim, Wright, Paul, West, Kate, Bright, Helen
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2011
Sujets:
Vaccine Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3187041/
https://ncbi.nlm.nih.gov/pubmed/21852545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.05071-11
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires